Alpha-2a adrenergic receptor activation in genetic absence epilepsy: An absence status model?

Melis Yavuz1, Serdar Akkol2, Filiz Onat3,4

  • 1Department of Pharmacology, Faculty of Pharmacy, Acibadem Mehmet Ali Aydinlar University University, Istanbul, Turkey.

Epilepsia Open
|December 10, 2023
PubMed
Abstract

Insights

This study introduces a new rat model for absence status epilepticus using alpha-2a adrenergic receptor (α2AR) activation. Atipamezole effectively reduced seizures without sedation, suggesting potential for targeted epilepsy treatment.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Absence status epilepticus (ASE) is a severe epileptic condition characterized by prolonged seizures.
  • Existing animal models may not fully recapitulate the complexity of human ASE.
  • Alpha-2a adrenergic receptors (α2AR) play a role in regulating neuronal excitability.

Purpose of the Study:

  • To develop a novel animal model of ASE by activating α2AR.
  • To investigate the efficacy of established anti-epileptic drugs in this new model.
  • To explore the potential of α2AR modulation in managing ASE.

Main Methods:

  • Intracerebroventricular injection of dexmedetomidine (DEX), an α2AR agonist, in rats with genetic absence epilepsy.
  • Electroencephalography (EEG) recording to analyze spike-and-wave discharges (SWDs).
  • Administration of anti-epileptic drugs (ethosuximide, valproic acid, diazepam, atipamezole) to assess their effects on DEX-induced seizures.

Main Results:

  • DEX (2.5 μg) induced continuous SWDs lasting up to 26 minutes, mimicking ASE.
  • Ethosuximide pretreatment prevented ASE induction.
  • Atipamezole, an α2AR antagonist, effectively terminated ASE-like activity without causing sedation.

Conclusions:

  • A novel rat model for ASE induced by α2AR activation has been established.
  • This model is responsive to classical anti-absence medications.
  • Atipamezole demonstrates potential as a targeted therapeutic agent for ASE, offering seizure control without significant side effects.

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
191
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
310
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.6K
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.6K